Market research
ARPO Aerpio Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 22
- Dividend yield
- 0.0%
- Beta
- 1.65
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 105M
- P/E ratio
- Not available
- Analyst target
- 22
- Dividend yield
- 0.0%
- Beta
- 1.65
About
About Aerpio Pharmaceuticals Inc
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
Research context
Aerpio Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ARPO discussion.
5 years, 6 months ago
Aerpio Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 85.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.
Aerpio Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 6.1% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 0.9% to $-5M since the same quarter in the previous year.
Based on the above factors, Aerpio Pharmaceuticals, Inc gets an overall score of 3/5.